Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIP chemotherapy for unresectable intrahepatic cholangiocarcinoma
NL-OMON52590Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine in intrahepatic cholangiocarcinoma (ICC), sponsored by Erasmus MC. Primary endpoint: Overall survival. Started Dec 2019; status: completed.
02
Drugs
floxuridine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NL-OMON52590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52590.